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Running title: Epidemiology of pain in people with dementia living in care homes 
Abstract 
Introduction Knowledge regarding the longitudinal course, impact, or treatment implications 
of pain in people with dementia living in care homes is very limited. 
Methods We investigated the people with dementia living in 67 care homes in London and 
Buckinghamshire, UK. Pain, dementia severity, neuropsychiatric symptoms, depression, 
agitation, and quality-of-life were measured using appropriate instruments at baseline (N=967) 
and after nine months (n=629).  
Results Baseline prevalence of pain was 35.3% (95%CI 32.3-38.3). Pain severity was 
significantly correlated with dementia severity, neuropsychiatric symptoms, depression, 
agitation, and quality-of-life at both time-points. Regular treatment with analgesics 
significantly reduced pain severity. Pain was significantly associated with more antipsychotic 
prescriptions. Pain was significantly associated (OR=1.48; 95%CI 1.18-1.85) with all-cause 
mortality during follow-up. 
Conclusions Pain is an important determinant of neuropsychiatric symptoms, mortality, 
quality-of-life, and antipsychotic prescriptions. Improved identification, monitoring, and 
treatment of pain are urgent priorities to improve the health and quality-of-life for people with 
dementia. 
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Introduction 
There are 850,000 people with dementia in the UK, representing a major public health issue 
that costs the UK economy over £26 billion each year 1. One third of people with dementia 
reside in long-term care facilities 2. These individuals have highly complex treatment and care 
needs resulting from moderate to severe dementia, associated mental health symptoms, medical 
comorbidity, and communication difficulties 3. Pain is common in people with dementia living 
in care homes, and is a major contributor to the challenge of care. Pain is often associated with 
medical co-morbidities, particularly musculoskeletal conditions and long-term neuropathic 
conditions such as diabetes 4,5. Despite widely available treament options, pain is often 
unrecognised or untreated because of difficulties in identifying and assessing pain in this 
patient group. Impairment in verbal communication, and insight into their condition is inherent 
in the later stages of dementia, thus hindering timely diagnosis and effective pain management 
6.  
 
Despite the importance of pain as a key driver of health and wellbeing in people with dementia 
in care homes, there is a concerning lack of consensus regarding its prevalence and 
epidemiology in these settings. Within the evidence base, studies principally evaluating the 
prevalence, nature, and mental health correlates of pain in people with dementia living in care 
homes are few in number, and usually based on modest  samples 5,7, often including people 
without dementia, with disparate prevalence estimates for pain ranging from 19.8% to 73.0% 
8,9. Three large longitudinal studies have been published, involving 3926, 5761, and 372 care 
home residents across European care homes, and reporting a prevalence of pain of 48.4%, 50%, 
and up to 67.6% respectively 7-9. However, none of these studies employed validated 
observational pain assessment instruments designed specifically for measuring pain in people 
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with dementia and communication difficulties, and thus detailed interpretation of the outcomes 
cannot be made 8,9. 
 
Initial evidence suggests that pain may be associated behavioural symptoms 10 including 
agitation, aggression, and depression 11,12, and the risk of polypharmacy in people with 
dementia. These issues are major drivers of Quality of Life (QoL), which suggests a potential 
association, but no study has examined the specific impact of pain and its intensity on QoL. 
More robust studies are needed to establish the true correlations between pain and these 
important health-related outcomes. To date, no study has utilised standardised measures of 
neuropsychiatric symptoms to examine association with pain.  
 
There is a clear need for robust evaluation of the epidemiology, associations and impacts of 
pain in people with dementia to build on the current evidence base and inform the development 
of optimal pathways for assessment, monitoring and treatment. Despite the importance of pain 
as a clinical issue in dementia, the guidance available for physicians is limited. A recent review 
of available guidelines has identified only three clinical guidelines for managing pain in 
dementia, of which none are tailored for the unique environment presented by a care home 6. 
Such lack of robust clinical guidelines adds to the difficulties in optimally managing pain and 
related mental health symptoms in this population, and highlights the need to fully understand 
the issues around pain management in this setting. Hence, this research aimed to conduct the 
first comprehensive large longitudinal study examining the nature, prevalence, and impact of 
pain exclusively in people with dementia living in care homes using a validated pain measure, 
and to assess the longitudinal course of pain and its associations with mental health symptoms 
and quality of life in people with dementia.  
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Methods & Materials 
 
Study design 
 This longitudinal study used data from the Well-being and Health for People with Dementia 
(WHELD) NIHR programme, and has been ethically approved (National Research Ethics 
Service Committee South Central - Oxford C Reference: 13/SC/0281).  
 
Setting 
 67 care homes were recruited across sites in South London, North London, and 
Buckinghamshire, UK. Suitable care homes were initially searched using local care home 
directories. Care homes were included, if at least 60% of their residents had dementia and they 
demonstrated minimum acceptable standard of care according to the Care Quality Commission 
(CQC). Care homes that received local authority special support, had insufficient staffing 
resource, were undergoing systematic service improvement programmes or another research, 
or anticipated major internal changes within the next 12 months were excluded. Consent for 
care home involvement was obtained from the management of the homes. 
 
Participants 
 All residents in the particapting care homes meeting diagnostic criteria for dementia, and 
having a score of one or greater on the Clinical Dementia Rating Scale (CDRS)13 were invited 
to participate. If residents lacked capacity, informed consent was obtained with the 
involvement of a nominated or personal consultee, who represented the residents’ interests, 
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and wishes in accordance with the Mental Capacity Act, 2005. Cluster sizes (the number of 
recruited participants per care home) varied from 12 to 25 participants.  
 
Outcome measures 
 Pain was assessed using the Abbey pain scale (APS)14. APS is a brief observational pain 
assessment instrument, designed specifically for measuring pain in people with dementia, who 
cannot verbalise. APS includes six non-verbal indicators of pain, vocalisation, facial 
expression, change in body language, behavioural change, physiological change, and physical 
changes, which are rated absent (0), mild (1), moderate (2), or severe (3). Total APS score 
ranges from zero to 18, and pain is considered to be present when the total APS score is three 
and above. Total scores between three and seven indicate mild pain, moderate pain is defined 
as scores between eight and 13, and severe pain is defined as a score of 14 and above. APS also 
categorises the type of pain as acute, acute on chronic, or chronic14. The Functional Assessment 
Staging Tool (FAST)15, a validated functional assessment scale in people with dementia, was 
employed to assess the severity of dementia. Agitation, depression, and mental health 
symptoms in dementia of the participants were evaluated using the Cohen-Mansfield Agitation 
Inventory (CMAI)16, Cornell Scale for Depression in Dementia (CSDD) 17, and 
Neuropsychiatric Inventory-Nursing Home version (NPI-NH)18, respectively. QoL of the 
participants were systematically assessed by the caregiver version of assessment of quality of 
life for people with dementia (DEMQoL-Proxy)19, and by the Quality of Life in Late-Stage 
Dementia (QUALID) scale20. Higher DEMQoL-Proxy scores indicate better QoL, while lower 
QUALID scores reflect better QoL. Trained research assistants completed the assessments at 
baseline, and after nine months. 
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Statistical analyses 
 Participants’ characteristics, their clinical profile, and APS scores were initially analysed by 
descriptive statistics. Differences between subgroups were analysed by appropriate tests of 
statistical significance. Correlations between APS scores and FAST, CSDD, CMAI, 
DEMQoL-Proxy, and QUALID scores were assessed using Spearman's rank-order correlation 
with Bonferroni corrections at baseline and at the follow-up. Associations between the changes 
in pain severity and the changes in mental health symptoms and QoL were evaluated using 
three-level mixed effects linear regression models with maximum likelihood estimation 
method. These models included age, gender, baseline FAST stage, and regular treatment with 
analgesics at baseline as covariates. Individual participants were nested within a level, the 
nursing homes, that in turn nested within a higher level, the three recruiting sites. Although 
FAST stages were naturally ordered, they were modelled as linear effects to increase the power 
of the statistical analyses. Clustered robust standard errors for the estimated regression 
coefficients were calculated with the recruiting sites as the clustering variable. Association 
between the presence of pain at baseline and all-cause mortality during follow-up was analysed 
by a three-level mixed effects logistic regression model. All analyses were performed using the 
statistical software STATA 13.1 (StataCorp, Texas, USA). 
 
Results 
 
Participant characteristics 
 967 people with dementia living in 67 nursing homes were included in this study, of whom 
629 (65.0%) completed follow-up at nine months. Among the 338 (35.0%) participants that 
did not complete the study, 125 (13.0%) withdrew, and 213 (22.0%) died during follow-up. 
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The participants, who withdrew, did not differ significantly (χ2=0.15; df=1; p=0.70) from 
others on the presence of pain at baseline. Table-1 presents the socio-demographic and clinical 
characteristics of the participants with and without pain at baseline.  
 
Prevalence and nature of pain 
 341 participants (35.3%) had pain, defined by total APS score of three and above, at baseline. 
The majority of participants had mild pain, which was predominantly chronic (Table-2). 197 
participants experienced pain at nine months, with a similar predominance of mild chronic 
pain. Table-2 shows the full data regarding the prevalence and nature of pain among 
participants with mild, moderate, moderately severe, or severe dementia at baseline and follow-
up.   
 
Treatment with analgesics 
 377 (39.0%; 95%CI 35.9 to 42.1%) participants had received regular analgesics at least for 
one month at baseline. 245 (65.0%) of them completed follow-up. Among the completers, 171 
(69.8%; 95%CI 64.1 to 75.6%) participants were receiving regular analgesics at follow-up, and 
74 (30.2%; 95%CI 24.5 to 36.0%) stopped receiving regular analgesics. 109 (28.4%) of the 
384 completers, who had not received analgesics at baseline, had started regular analgesics at 
follow-up. Regular treatment with analgesics at baseline significantly reduced the severity of 
pain (β=-0.88; 95%CI -1.57 to -0.20; p=0.01) at the follow-up, after adjusting for the effects of 
age, gender, and baseline severity of dementia.  
 
Longitudinal course and correlates of pain 
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Participants with and without pain at baseline did not differ significantly in their gender, age, 
ethnicity, or the number of years lived in the care homes. People experiencing pain showed 
significantly higher agitation, depressive symptoms, overall mental health symptoms, and 
worse QoL at baseline and follow-up after Bonferroni corrections, and significant associations 
were also demonstrated between changes in pain and changes in these symptoms (Table 3, 
Table 4). Change in pain severity was significantly associated with the changes in the NPI-NH 
domain C (Agitation/Aggression) scores of participants that completed follow-up, after 
adjusting for the effects of age, gender, baseline dementia severity, and baseline treatment with 
analgesics. The associations between the changes in pain severity and the changes in other NPI-
NH domain scores of participants that completed follow-up were not statistically significant 
(Table 5). 
Participants experiencing pain at follow-up were significantly more likely to receive 
antipsychotics (χ2=3.92; df=1; p=0.048). Pain at baseline was significantly associated 
(OR=1.48; 95%CI 1.18 to 1.85; p=0.001) with all-cause mortality during follow-up. This 
association remained statistically significant (AOR=1.34; 95%CI 1.07 to 1.68; p=0.01) after 
adjusting for the effects of age, gender, and baseline dementia severity. Analgesic treatment 
was common within the cohort, with the largest proportion of participants receiving regular 
paracetamol, a considerable number receiving non-steroidal anti-inflammatories and opioids 
and a small number receiving gabapentin, topical analgesia and neutraceutical preparations for 
joint pain.  
 
 
 209 participants who experienced clinically significant pain completed the study, of whom 82 
(39.2%) showed significant pain at follow-up. Pain resolved in 127 (60.8%) participants. 115 
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(27.4%) of the 420 participants, who completed the study and did not have pain at baseline, 
developed incident pain. Table 6 presents socio-demographic and clinical profiles of the 
participants with persistent or resolved pain. Participants with more severe pain and associated 
mental health symptoms at baseline were significantly more likely to suffer from persistent 
pain at follow-up. Moreover, persistent pain was associated with greater agitation, depressive 
symptoms, overall mental health symptoms and worse QoL than participants, whose pain 
resolved, at the follow-up. Among the 98 completers with chronic pain at baseline 48 (49.0%) 
experienced pain at follow-up. Among the 111 completers with acute or acute on chronic pain 
at baseline, 39 (35.1%) experienced pain at follow-up. 
 
 
Discussion 
This study is the largest longitudinal study conducted to date that has utilised validated scales 
to establish the prevalence, impact, and associations of clinically-significant pain, and key 
health-related outcomes in people with dementia living in care homes. The study confirms the 
widespread prevalence of pain in this group, and provides robust data regarding the 
longitudinal course of pain, and its association with severity of dementia, neuropsychiatric 
symptoms. and all-cause mortality of people with dementia, after adjusting for the effects of 
potential confounders. Importantly, it is also the first study to report the longitudinal association 
between severity of pain and QoL.  
 
Several novel findings have implications for practice. Firstly, it is interesting to note the 
considerable fluctuation of pain within the cohort, with a significant proportion of individuals 
experiencing resolution of pain or developing incident pain. These findings highlight the 
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complexity and subjectivity of pain as a clinical condition, particularly when it is linked to 
multiple co-morbidities, and thus part of a complex set of interrelated symptoms. This work 
clearly indicates the importance of regularly assessing pain on an ongoing basis in order to 
optimise the identification and treatment of pain, and maximise the knock-on effect on QoL, 
neuropsychiatric symptoms, and mortality in these individuals21-24. The study also reports a 
clear association between pain and increased antipsychotic use, which may be related to mis-
diagnosis or mistreatment of pain in these individuals, and further highlights the importance of 
prompt assessment. 
 
Secondly, the study also reports improved outcome of pain in people receiving analgesics at 
baseline, which highlights the value of prompt analgesic treatment in this patient group. There 
are few studies of analgesia in people with dementia, and the majority are focussed on the 
impact of treatment on neuropsychiatric symptoms rather than ongoing pain. This work 
indicates the potential for sustained benefit of analgesics on persistent pain, which warrants 
further investigation. Finally, there is a distinct group of individuals within the cohort with both 
neuropsychiatric symptoms and pain at baseline who continued to experience persistent pain 
at follow-up. This is an important patient group with multi-morbidity, who should be prioritised 
for intensive treatment and monitoring, and for whom specific treatment pathways are needed.  
 
These findings offer the rationale for clear, accessible, tailored guidance for use in care home 
settings, indicating the importance of pain assessment and treatment in addressing or reducing 
the risk of other clinically relevant health outcomes such as behaviour and mortality. Despite 
the availability of caregiver rating and observational assessment instruments, they are not 
regularly used in practice. This study has demonstrated the concurrent validity of pain, assessed 
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using the APS, which is a brief and simple tool that is commonly available in care homes25. 
These findings indicate that promotion of the APS for general use by staff as part of pain 
management guidance would be a positive step towards regular, accurate pain assessment in 
usual care. There is a clear need to ensure care staff at all seniorities and positions receive clear, 
evidence-based training on assessing, managing, and treating pain in people with dementia, 
including understanding the fluctuating nature of pain, and recognising high priority, and at-
risk individuals for rapid treatment. No such training or management interventions currently 
exist, and there is a concerning lack of accessible guidance in the UK or worldwide, particularly 
for care home settings6.  Any new guidance should be informed by the outcomes of this study 
in addition to the growing body of evidence relating to timely assessment and effective non-
drug and pharmacological treatment options for use in care home settings. 
 
The study both confirms and provides novel data regarding the association of pain with key 
health-related outcomes. Prevailing evidence clearly describes the associations between pain 
and agitation, physical aggression, depression, and overall mental health symptoms in 
dementia11,12,21-24. This pattern is confirmed in this study, which further provides a longer 
follow-up period, and more robust multivariate analysis in comparison to previously published 
studies. The findings also correlate with a recent small study in eight nursing facilities in 
Pennsylvania (N=103) which reported that people with dementia experiencing higher levels of 
pain had significantly higher rates (OR = 6.31; 95%CI 1.91 to 20.77) of all-cause mortality 
over three months. Our findings confirm this association with a larger sample size, longer 
duration of follow-up, and robust multivariate analysis. Association between severity of pain 
and mortality is difficult to interpret due to the low number of participants with severe pain at 
baseline (n=4). However, morality in people with mild and moderate pain at baseline were 
within a similar range. Importantly, to date no studies have systematically evaluated the 
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longitudinal association between severity of pain and QoL in people with dementia living in 
care homes. This study is the first to investigate and establish this link. Overall, the evidence 
of association between pain and key outcomes including major neuropsychiatric symptoms and 
QoL highlights the importance of pain in the overall health and wellbeing of people with 
dementia in care home settings. 
 
This study reports a prevalence of pain of between 35.3% and 31.3% across the time course. 
Interestingly, this is lower than the prevalence reported in previous studies in European nursing 
home residents including people with and without dementia (up to 50%)8,9, community-
dwelling individuals (63.5%)26, and acute care settings (up to 57.0%)27. It is also lower than 
figures of 47% to 68% published in smaller care home studies from the Netherlands and 
Northern Ireland5,7. This discrepancy is likely due to the clinically-relevant criteria that were 
followed in this study, ensuring that the diagnostic threshold of pain was determined by APS 
score. It may also be related to the inclusion criteria for the study which required homes to 
demonstrate a minimum acceptable standard of care according to the CQC. The lower pain 
prevalence may also be related to the 39% use of analgesics at baseline.  
 
This is a large, robust study that provides novel and important data within the field. The study 
has clear strengths, including the robust design, large sample size, high retention of surviving 
participants and long follow-up period compared with previous studies, in addition to the 
precision of the design which ensured the exclusive recruitment of people with dementia living 
in care homes and assessment of pain through a validated, sensitive and appropriate 
observational pain assessment instrument. Selection bias was minimised by including all 
eligible consenting residents in the participating care homes. There are limitations to 
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acknowledge. Further data on the type and dosage of analgesics were not available, including 
reasons for halting their use during the period of the study, and the pragmatic nature of this 
trial allowed including people with multiple concurrent medications. Furthermore, our analyses 
considered all subtypes of dementia as one category and it may be of interest to investigate the 
patterns reported here in various subtypes of dementia in the future. 
 
 
Conclusions 
The study confirms the widespread prevalence of pain amongst people with dementia living in 
care homes, and provides novel data regarding the longitudinal course of pain and its 
association with severity of dementia, neuropsychiatric symptoms, all-cause mortality and 
QoL. The clear association between pain and these key health outcomes highlights the 
importance of pain in the overall health and wellbeing of people with dementia in care home 
settings and the need to improve guidance on pain management in these settings. 
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Table 1: Socio-demographic and clinical characteristics of the people with dementia, who suffered from paina, and those, who did not experience 
pain at baseline (N=967) 
 
Characteristic 
With paina (n=341) 
n (%) / Mean (SD) 
Without pain 
(n=626) 
n (%) / Mean (SD) 
χ2 (df)/ zb p value 
Female gender 251 (73.6) 432 (69.0) 2.25 (1) 0.13 
Age in years 85.28 (8.71) 84.17 (9.13) -1.56b 0.91 
Ethnicity: White 322 (94.4) 590 (94.3) 0.01 (1) 0.91 
Number of years lived in nursing homes 2.31 (2.19) 2.41 (2.35) 0.37b 0.71 
 
FAST 
Mild 25 (7.3) 63 (10.1)  
16.26 (3) 
 
0.001 Moderate 19 (5.6) 67 (10.1) 
Moderately severe 196 (57.5) 368 (58.8) 
Severe 101 (29.6) 128 (20.5) 
Abbey pain scale total score 5.40 (2.50) 0.60 (0.81) -26.57b <0.001 
NPI-NH total score  18.12 (16.89) 12.07 (13.00) -5.95b <0.001 
CMAI total score 53.54 (22.42) 45.46 (16.86) -5.68b <0.001 
CSDD total score 8.52 (5.39) 4.98 (4.43) -10.49b <0.001 
DEMQoL total score 98.41 (13.50) 103.16 (12.33) 5.63b <0.001 
QUALID total score 24.86 (7.66) 19.80 (6.68) -10.41b <0.001 
Co-morbid mental health diagnoses 73 (21.4) 109 (17.4) 2.31 (1) 0.13 
Treatment with analgesicsc  198 (58.1) 179 (28.6) 80.60 (1) <0.001 
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Currently on antipsychotic medication 61 (17.9) 97 (15.5) 0.93 (1) 0.34 
a Abbey pain scale total score three and above; b Two-sample Wilcoxon rank-sum test z value; c Participant has been receiving regular treatment 
with analgesics at least for a month at baseline. Analgesic treatments included: Paracetamol, Non-Steroidal Anti-inflammatories, Opioids, Topical 
administrations, Gabapentin and neutraceutical preparations; FAST: Functional assessment staging test; NPI-NH: Neuropsychiatric inventory-
nursing home version; CMAI: Cohen-Mansfield agitation inventory; CSDD: Cornell scale for depression in dementia; DEMQoL: Assessment 
(Proxy) of quality of life for people with dementia; QUALID: Quality of life in late-stage dementia scale. 
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Table 2: Prevalence and nature of paina among the participants with differing levels of severity of dementiab at baseline (N=967) and at the follow-
up (n=629) 
Nature of pain Mild n (%) Moderate n (%) Moderately severe n (%) Severe n (%) 
Baseline 
(n=88) 
Follow-up 
(n=52) 
Baseline 
(n=86) 
Follow-up 
(n=32) 
Baseline 
(n=564) 
Follow-up 
(n=345) 
Baseline 
(n=229) 
Follow-up 
(n=200) 
Mildc 23 (26.1) 4 (7.7) 15 (17.4) 3 (9.4) 153 (27.1) 98 (28.4) 85 (37.1) 59 (29.5) 
Moderated 2 (2.3) 0 (0.0) 4 (4.7) 0 (0.0) 40 (7.1) 17 (4.9) 15 (6.6) 12 (6.0) 
Severee 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (0.5) 1 (0.3) 1 (0.4) 3 (1.5) 
Acute 9 (10.2) 2 (3.9) 5 (5.8) 1 (3.1) 51 (9.0) 23 (6.7) 32 (14.0) 22 (11.0) 
Acute on chronic 3 (3.4) 0 (0.0) 3 (3.5) 1 (3.1) 57 (10.1) 15 (4.4) 18 (7.9) 11 (5.5) 
Chronic 13 (14.8) 2 (3.9) 11 (12.8) 1 (3.1) 88 (15.6) 78 (22.6) 51 (22.3) 41 (20.5) 
Total scoref (Mean (SD)) 1.60 (0.26) 0.71 (0.17) 1.53 (0.26) 0.56 (0.21) 2.40 (0.12) 2.24 (0.15) 2.59 (0.18) 2.59 (0.22) 
 
a Pain was assessed by the Abbey pain scale (APS); b Severity of dementia was assessed by the Functional assessment staging test (FAST); c Total 
APS scores between three and seven; d Total APS scores between eight and 13; e Total APS scores 14 and above; f Total APS score. 
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Table 3: Clinical correlates of paina among people with dementia living in nursing homes at 
baseline (N=967) and at the follow-up (n=629) 
Clinical variable Baseline Follow-up 
ρb pc ρb pc 
Age in years 0.04 1.00 0.03 1.00 
FAST stage 0.14 < 0.001 0.19 < 0.001 
NPI-NH total score 0.19 < 0.001 0.27 < 0.001 
CMAI total score 0.19 < 0.001 0.31 < 0.001 
CSDD total score 0.37 < 0.001 0.40 < 0.001 
DEMQoL total score -0.22 < 0.001 -0.30 < 0.001 
QUALID total score 0.36 < 0.001 0.40 < 0.001 
 
a Abbey pain scale total score; b Spearman correlation coefficients; c p values after Bonferroni 
correction for multiple testing; FAST: Functional assessment staging Test; NPI-NH: 
Neuropsychiatric inventory-nursing home version; CMAI: Cohen-Mansfield agitation 
inventory; CSDD: Cornell scale for depression in dementia; DEMQoL: Assessment (Proxy) of 
quality of life for people with dementia; QUALID: Quality of life in late stage dementia scale.  
 
 
 
 
 
 
Table 4: Associations between changes in pain severitya and changesb in neuropsychiatric 
symptoms as well as quality of life of participants that completed follow-up (n=629) 
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Dependent variablec βd 95% CI of βe z p  
CMAI total score 0.69 0.19 – 1.19 2.73 0.006 
Physically aggressive behavioursf 0.26 0.10 – 0.41 3.25 0.001 
Physically non-aggressive behavioursf 0.16 -0.08 – 0.40 1.29 0.196 
Verbally aggressive behavioursf 0.09 -0.02 – 0.20 1.66 0.097 
Verbally non-aggressive behavioursf 0.13 -0.07 – 0.33 1.25 0.211 
NPI-NH total score 0.29 0.06 – 0.52 2.51 0.012 
CSDD total score 0.44 0.34 – 0.54 8.28 < 0.001 
DEMQoL total score -0.59 -0.68 – -0.51 -13.81 < 0.001 
QUALID total score 0.60 0.43 – 0.76 6.97 < 0.001 
a Abbey pain scale (APS) total score at baseline was subtracted from APS total score at the 
follow-up; b Scores at baseline were subtracted from corresponding scores at the follow-up; c  
Each row represents a three-level mixed effects linear regression model with maximum 
likelihood estimation method. Change in pain severity between the two time-points was 
included as the independent variable. Age and gender of participants, baseline dementia 
severity, measured by Functional Assessment Staging Test, and baseline treatment with 
analgesics were included as co-variates. Individual participants were nested within a level, the 
nursing homes, that in turn nested within a higher level, the sites; d Regression coefficients; e 
Clustered robust standard errors were calculated with the sites as the clustering variable; f 
Subscale of Cohen-Mansfield Agitation Inventory (CMAI); NPI-NH: Neuropsychiatric 
inventory- nursing home version; CSDD: Cornell scale for depression in dementia; DEMQoL: 
Assessment (Proxy) of quality of life for people with dementia; QUALID: Quality of life in 
late stage dementia scale.  
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Table 5: associations between the changes in pain severitya and the changes in each of these 
NPI-NH domainsb of participants that completed follow-up. 
Dependent variablec βd 95% CI of βe z p  
A. Delusions 0.03 -0.03 – 0.08 1.04 0.30 
B. Hallucinations 0.01 -0.02 – 0.05 0.71 0.48 
C. Agitation/Aggression 0.12 0.06 – 0.17 3.99 < 0.001 
D. Depression/Dysphoria 0.06 -0.01 – 0.13 1.80 0.07 
E. Anxiety -0.01 -0.05 – 0.04 -0.27 0.79 
F. Elation/Euphoria 0.02 -0.01 – 0.05 1.18 0.24 
G. Apathy/Indifference 0.05 -0.10 – 0.19 0.66 0.51 
H. Disinhibition 0.00 -0.04 – 0.04 0.13 0.90 
I. Irritability/Lability 0.03 -0.09 – 0.16 0.52 0.60 
J. Aberrant motor behaviour 0.01 -0.09 – 0.12 0.28 0.78 
NPI-NH total score 0.29 0.06 – 0.52 2.51 0.01 
a Abbey pain scale (APS) total score at baseline was subtracted from APS total score at the 
follow-up; b Scores at baseline were subtracted from corresponding scores at the follow-up; c  
Each row represents a three-level mixed effects linear regression model with maximum 
likelihood estimation method (mixed changeNPIA changepain  analgesicBLR age gender 
FASTBL if completedFU==1 || site: || CareHome_ID: , vce(cluster site) nolog). d Regression 
coefficients; e Clustered robust standard errors were calculated with the sites as the clustering 
variable. 
 
Table 6: Socio-demographic and clinical profile of the people, who experienced persistent 
paina (n=82), and the people, whose pain resolvedb (n=127) at the follow-up 
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Characteristic 
Persistent paina 
n (%) /  
Mean (SD) 
Resolving painb 
n (%) /  
Mean (SD) 
χ2 (df)/ 
zc 
 
p value 
Female gender 65 (79.3) 92 (72.4) 1.24 (1) 0.27 
Age in years at baseline 83.57 (9.48) 84.95 (8.67) 0.60c 0.55 
Ethnicity: White 76 (92.7) 119 (93.7) 0.08 (1) 0.77 
 
FAST at 
baseline 
Mild 6 (7.3) 13 (10.2)  
5.74 (3) 
 
0.13d Moderate 9 (11.0) 4 (3.2) 
Moderately severe 44 (53.7) 76 (59.8) 
Severe 23 (28.1) 34 (26.8) 
APS score at baseline 5.90 (2.80) 4.96 (2.18) -2.38c 0.02 
Type of 
pain at 
baseline 
Acute 18 (22.0) 45 (35.4)  
4.30 (2) 
 
0.12 Acute on chronic 21 (25.6) 27 (21.3) 
Chronic 43 (52.4) 55 (43.3) 
NPI-NH 
total score  
Baseline 22.27 (19.76) 15.12 (14.48) -2.94c 0.003 
Follow-up 20.37 (16.25) 12.34 (13.67) -4.14c <0.001 
CMAI total 
score 
Baseline 58.83 (23.82) 51.20 (20.46) -2.51c 0.01 
Follow-up 55.74 (21.05) 46.21 (20.15) -4.13c <0.001 
CSDD total 
score 
Baseline 9.56 (5.46) 7.37 (4.93) -2.91c 0.004 
Follow-up 7.02 (5.18) 4.17 (4.09) -4.45c <0.001 
DEMQoL 
total score 
Baseline 96.22 (13.99) 100.70 (13.03) 2.47c 0.01 
Follow-up 99.20 (13.09) 106.63 (9.91) 5.02c <0.001 
QUALID 
total score 
Baseline 26.49 (7.70) 22.76 (6.82) -3.59 <0.001 
Follow-up 26.44 (8.39) 19.92 (6.09) -5.93 <0.001 
Comorbid mental health 
diagnoses at baseline 
21 (25.6) 25 (19.7) 1.02 (1) 0.31 
Receiving 
analgesicse 
Baseline 52 (63.4) 72 (56.7) 0.93 (1) 0.33 
Follow-up 53 (64.6) 69 (54.3) 2.18 (1) 0.14 
Receiving 
APD 
Baseline 16 (19.5) 23 (18.1) 0.06 (1) 0.80 
Follow-up 15 (18.3) 19 (15.0) 0.41 (1) 0.52 
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a Abbey pain scale (APS) total score three and above at both time-points; b APS total score was 
three and above at baseline, but it was less than three at the follow-up; c Two-sample Wilcoxon 
rank-sum test z value; d Fisher’s exact test p value was 0.138; e Participant has been receiving 
regular treatment with analgesics at least for a month; FAST: Functional assessment staging 
test; NPI-NH: Neuropsychiatric inventory-nursing home version; CMAI: Cohen-Mansfield 
agitation inventory; CSDD: Cornell scale for depression in dementia; DEMQoL: Assessment 
(Proxy) of quality of life for people with dementia, APD: Antipsychotic Drugs
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